Abstract Information
Titles of Regular Abstracts and Young Investigator Award (YIA) Abstracts will be available on Sept. 27, 2023, 9 a.m. EDT, titles of Regular Abstracts - Part 2 will be available on Oct. 18, 2023, 9 a.m. EDT, and titles of Late-breaking Abstracts will be available on Oct. 25, 2023, 9 a.m. EDT on the SITC Annual Meeting website. Once abstract titles are listed on the website, press releases can be issued with the titles and logistical information.
Accepted Regular and Late-breaking Abstracts will be published in the Journal for ImmunoTherapy of Cancer (JITC) as a supplement at 9 a.m. EDT on Tuesday, Oct. 31, 2023.
Embargo
In an effort to assist registered members of the press with planning coverage, SITC issues press releases and provides abstract summaries in advance of the Annual Meeting. In addition, SITC allows companies and institutions to disseminate press releases; however, all materials are embargoed according to the following:
-
Abstract Title Embargo: Titles of abstracts submitted to SITC are embargoed until titles are made public on the SITC website
-
Regular Abstracts and Young Investigator Award (YIA) Abstracts: Sept. 27, 2023, at 9 a.m. EDT
-
Regular Abstracts - Part 2: Oct. 18, 2023, 9 a.m. EDT
-
Late-breaking Abstracts: Oct. 25, 2023, at 9 a.m. EDT
-
Abstract Content Embargo: Abstract content is embargoed until Oct. 31, 2023, at 6 a.m. PDT/9 a.m. EDT
-
Poster Embargo: Any additional data that will be available on a poster that is beyond what was submitted in the abstract is embargoed until Nov. 3, 2023, at 9 a.m. PDT/12 p.m. EDT. This embargo applies to poster-only presentations.
-
Oral Presentation Data Embargo: Any updated and/or new data that will be available in an oral presentation is embargoed until the date and time of the presentation. If the oral presenter is also creating a poster which includes updated and/or new data, the poster shares the same Oral Presentation Embargo date, not the poster embargo date specified above. This embargo applies to oral abstract presentations.
Embargo Policy Exceptions:
In the event that a publicly traded company is required to disclose data or other information from an embargoed abstract in advance of the embargo date to satisfy the requirements of the US Securities and Exchange Commission (SEC) or a corresponding international body, the abstract will still be eligible for inclusion in the SITC Annual Meeting. The company must provide written notification to SITC of the SEC requirements in advance of releasing information to satisfy SEC or corresponding international body’s requirements by emailing the SITC Education team (education@sitcancer.org) and the SITC Press Office (communications@sitcancer.org).
For more information, please review the SITC 2023 Media Policy.
Press Registration
Any individual who wanted to register as press for the 38th Annual Meeting & Pre-Conference Programs (SITC 2023) must complete and submit the press registration form. Your press credentials and/or letter of assignment are required onsite to secure a press badge. No exceptions will be allowed.
Submitting the press registration form does not guarantee receipt of a complimentary press pass, and press passes are not granted to anyone whose principal purpose for attending the event is—in our judgment—for reasons other than covering it as working news media. Advertising and marketing representatives, as well as editors attempting to solicit papers for competing journals, will not be allowed to register as press.
Press passes/registration for the event(s) only allow access to the virtual common meeting areas and virtual general session rooms with speakers offering educational content. At the event SITC provides a media room at SITC 2023, your press pass will also gain you entry as a dedicated work space while onsite. Attendance and coverage of private meetings associated with the event are not allowed without permission from SITC executive management.
Press Registration Instructions
Onsite Policies and Regulations
-
Photography/videography is allowed with an approved press registration in the virtual exhibit hall and general conference space outside of the virtual session rooms
-
Photography/videography of meeting proceedings (slides or presenters) in the virtual educational session rooms is only allowed with prior written permission granted by SITC
-
Members of the press can utilize personal audio recording devices in the virtual session rooms strictly for note taking purposes. Release of the recordings in part or in whole is prohibited
-
If there is a particular presentation of interest and you wish to obtain the slide(s), you can speak directly with individual presenters and request that they share the slide(s) of interest to you. Please note, approved slides will be made available to meeting attendees four to six weeks after the meeting
-
Photography/videography in the virtual poster hall and of specific posters is only allowed if permission is granted by the poster presenter(s)
-
Press wishing to obtain interviews and official statements on behalf of the society must work with the SITC Communications Department (requests can be submitted to communications@sitcancer.org) for scheduling with the appropriate official representatives
-
SITC President Leisha Emens, MD, PhD, is the official spokesperson of the Society for Immunotherapy of Cancer. She is the approved representative who may speak on behalf of the society, unless otherwise approved by SITC administration
Press Resources
Visit the SITC Media Room for online access to the latest SITC press releases, cancer immunotherapy news and additional resources.
For more information, please contact the SITC Office at +1 414 271 2456 or communications@sitcancer.org.